Selenoprotein P is not elevated in gestational diabetes mellitus

Altınova, Alev Eroğlu; İyidir, Özlem Turhan; Özkan, Çiğdem; Ors, Damla; Öztürk, Merve; Gülbahar, Özlem; Bozkurt, Nuray; Törüner, Füsun Baloş; Aktürk, Müjde; Çakır, Nuri; Arslan, Metin

doi:10.3109/09513590.2015.1103220

Cited by 16 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, di Giuseppe et al, based on MRI imaging, noted inverse relations of serum selenoprotein P concentrations with several metabolic indices [ 42 ]. Furthermore, Altinova et al did not show any difference in SeP level in diabetic versus non-diabetic pregnant women [ 23 ]. Finally, Polyzos et al in a recently published study revealed decreased SeP levels in patients with definite NASH (nonalcoholic steatohepatitis) compared with controls, and they did not rely on the severity of steatosis, fibrosis or lobular and portal inflammation [ 43 ].…”

Section: Discussionmentioning

confidence: 99%

“…Increased hepatic SeP has been related to reduced glucose tolerance as well as higher fasting glucose levels [ 3 , 21 ]. On the other hand, as some researchers suggested that increased SeP concentrations may be a secondary condition to DM or reported contradictory outcomes, it seems highly possible that SeP is involved in glucose homeostasis and metabolic disorders, although not many definite conclusions can be drawn [ 12 , 22 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Higher Serum Selenoprotein P Level as a Novel Inductor of Metabolic Complications in Psoriasis

Baran

Nowowiejska

Krahel

et al. 2020

IJMS

View full text Add to dashboard Cite

Selenoprotein P (SeP), a member of hepatokines, is involved in the development of various metabolic diseases closely related to psoriasis, but it has not been explored in that dermatosis so far. The study aimed to evaluate the clinical value of serum SeP concentrations in patients with psoriasis and its interplay between disease activity, metabolic or inflammatory parameters and systemic therapy. The study included thirty-three patients with flared plaque-type psoriasis and fifteen healthy volunteers. Blood samples were collected before and after three months of treatment with methotrexate or acitretin. Serum SeP levels were evaluated using the immune–enzymatic method. SeP concentration was significantly higher in patients with psoriasis than in the controls (p < 0.05). Further, in patients with severe psoriasis, SeP was significantly increased, compared with the healthy volunteers before treatment, and significantly decreased after (p < 0.05, p = 0.041, respectively). SeP positively correlated with C-reactive protein and platelets and negatively with red blood counts (p = 0.008, p = 0.013, p = 0.022, respectively). Therapy resulted in a significant decrease in SeP level. Selenoprotein P may be a novel indicator of inflammation and the metabolic complications development in psoriatics, especially with severe form or with concomitant obesity. Classic systemic therapy has a beneficial effect on reducing the risk of comorbidities by inhibiting SeP.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Higher Serum Selenoprotein P Level as a Novel Inductor of Metabolic Complications in Psoriasis

Baran

Nowowiejska

Krahel

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…An early paper showed that SELENOP concentrations were unchanged in pregnant women with gestational diabetes compared with those without gestational diabetes 10 . In that paper, the average HbA1c in pregnant women with gestational diabetes was 5.4%.…”

Section: Discussionmentioning

confidence: 99%

“…First, SELENOP concentrations were reported to be elevated in people with type 2 diabetes, prediabetes, and non-alcoholic fatty liver disease 1 , 8 , 9 . However, pregnant women with gestational diabetes showed unchanged plasma levels of SELENOP compared with those without gestational diabetes 10 . In young children, increased SELENOP concentrations were reported to be negatively associated with certain components of metabolic syndrome, such as waist circumference and blood pressure 11 .…”

Section: Introductionmentioning

confidence: 87%

Serum selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population

Makino

Saito

et al. 2018

Sci Rep

View full text Add to dashboard Cite

We aimed to test the hypothesis that selenoprotein P (SELENOP), a hepatokine involved in the development of both insulin resistance and impaired insulin production in mice, is related to future onset of hyperglycemia in humans. 76 healthy non-pregnant human subjects without diabetes underwent oral glucose tolerance test (OGTT) at baseline and 4-years follow-up. Nine subjects developed either impaired glucose tolerance or type 2 diabetes at follow-up. At baseline, SELENOP concentrations correlated negatively with insulinogenic index, but not with homeostasis model assessment-estimated insulin resistance (HOMA-IR). Multivariate analysis showed that baseline SELENOP predicted fasting plasma glucose at follow-up independently of the other parameters. The receiver operating characteristic (ROC) curve analysis showed that baseline concentrations of serum SELENOP, but not of selenium, were a reliable test to predict future onset of glucose intolerance. In conclusion, elevation of circulating SELENOP, but not of circulating selenium, was positively and independently associated with future onset of glucose intolerance in a general Japanese population.

show abstract

“…However, quantification of SELENOP is challenging, and reported serum concentrations of SELENOP differ considerably between assays and research laboratories. Recently, the following concentrations of SELENOP in serum or plasma of healthy subjects have been reported: 6.7 (5.3–9.1) µg/L in a Turkish [14], 362.0 (252.5–694.5) µg/L in a South Korean [15], 5.3±1.1 mg/L in a Japanese [16], and 52.3±39.1 mg/L in a Chinese/Australian study [17]. These concentration ranges differ by almost 4 orders of magnitude, highlighting that there is an urgent need for a better characterization and calibration of SELENOP assays used in clinical analyses, and a need for a uniformly accepted reference material.…”

Section: Introductionmentioning

confidence: 97%

Sex-specific and inter-individual differences in biomarkers of selenium status identified by a calibrated ELISA for selenoprotein P

Hybsier

Schulz²,

et al. 2017

Redox Biology

View full text Add to dashboard Cite

Selenoprotein P (SELENOP) is a liver-derived transporter of selenium (Se) in blood, and a meaningful biomarker of Se status. Se is an essential trace element for the biosynthesis of enzymatically-active selenoproteins, protecting the organism from oxidative damage. The usage of uncalibrated assays hinders the comparability of SELENOP concentrations and their pathophysiological interpretation across different clinical studies. On this account, we established a new sandwich SELENOP-ELISA and calibrated against a standard reference material (SRM1950). The ELISA displays a wide working range (11.6–538.4 µg/L), high accuracy (2.9%) and good precision (9.3%). To verify whether SELENOP correlates to total Se and to SELENOP-bound Se, serum samples from healthy subjects and age-selected participants from the Berlin Aging Study II were analyzed by SELENOP-ELISA and Se quantification. SELENOP was affinity-purified and its Se content was determined from a subset of samples. There was a high correlation of total Se and SELENOP concentrations in young and elderly men, and in elderly women, but not in young women, indicating a specific sexual dimorphism in these biomarkers of Se status in young subjects. The Se content of isolated SELENOP was independent of sex and age (mean±SD: 5.4±0.5). By using this calibrated SELENOP-ELISA, prior reports on pathological SELENOP concentrations in diabetes and obesity are challenged as the reported values are outside reasonable limits. Biomarkers of Se status in clinical research need to be measured by validated assays in order to avoid erroneous data and incorrect interpretations, especially when analyzing young women. The Se content of circulating SELENOP differs between individuals and may provide some important diagnostic information on Se metabolism and status.

show abstract

Selenoprotein P is not elevated in gestational diabetes mellitus

Cited by 16 publications

References 20 publications

Higher Serum Selenoprotein P Level as a Novel Inductor of Metabolic Complications in Psoriasis

Higher Serum Selenoprotein P Level as a Novel Inductor of Metabolic Complications in Psoriasis

Serum selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population

Sex-specific and inter-individual differences in biomarkers of selenium status identified by a calibrated ELISA for selenoprotein P

Contact Info

Product

Resources

About